Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HINT1 | P49773 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | PNP | P00491 | 2/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313652 | 1.00 | PDE4D (0.53) | PDE4DPDE3ASLC29A1ADORA3HPGD | |
| Phosphoric Acid SCHEMBL21465104 | 0.96 | NT5E (0.51) | PDE4DPDE3ASLC29A1ADORA3HPGD | |
| SCHEMBL546453 | 0.91 | ADORA3 (0.51) | PDE3AADORA3HPGDHINT1NT5E | |
| SCHEMBL4844756 | 0.91 | ADORA3 (0.51) | PDE3AADORA3HPGDHINT1NT5E | |
| SCHEMBL25380147 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A | |
| SCHEMBL19813683 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A | |
| SCHEMBL20991026 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A | |
| SCHEMBL471141 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A | |
| SCHEMBL13929032 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A | |
| SCHEMBL465582 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 535 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819718-A1 | DIFLUORONUCLEOSIDES AND PROCESS FOR PREPARATION THEREOF | Sicor Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| US-20060173174-A1 | Difluoronucleosides and process for preparation thereof | SICOR, INC. | 2006-08-03 | — | — | US | claimed |
| WO-2006063105-A1 | DIFLUORONUCLEOSIDES AND PROCESS FOR PREPARATION THEREOF | SICOR INC. (US) | 2006-06-15 | — | — | WO | claimed |
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE ARV TECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4727955-A1 | CYSTEINE-SUBSTITUTED RSV-F PROTEINS | GlaxoSmithKline Biologicals S.A. (BE) | 2026-04-22 | — | — | EP | disclosed |
| EP-3458081-B1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX INC (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015085318-A2 | TARGETED ADAPTIVE VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015058069-A1 | COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS | MODERNA THERAPEUTICS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015051214-A1 | POLYNUCLEOTIDES ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR | MODERNA THERAPEUTICS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015038892-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-1819718-A1 | DIFLUORONUCLEOSIDES AND PROCESS FOR PREPARATION THEREOF | Sicor Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060173174-A1 | Difluoronucleosides and process for preparation thereof | SICOR, INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006063105-A1 | DIFLUORONUCLEOSIDES AND PROCESS FOR PREPARATION THEREOF | SICOR INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | PDE4D 243/4885PDE3A 1044/4885SLC29A1 442/4885 |
| US-20060173174-A1 | Difluoronucleosides and process for preparation thereof | DUT, NUDT1, DPYD | PDE4D 1971/4885PDE3A 3246/4885SLC29A1 57/4885 |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, METTL16, NSUN2 | PDE4D 2437/4885PDE3A 3528/4885SLC29A1 934/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | PDE4D 3216/4885PDE3A 4081/4885SLC29A1 927/4885 |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | UPF1, NSUN2, CD4 | PDE4D 4236/4885PDE3A 4816/4885SLC29A1 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.